Dark Clouds Lift Over Pharma Dispute

The case of who bought whom in the Merck (NYSE: MRK  ) -Schering-Plough deal has ended in a draw.

In order to avoid triggering a change-in-ownership provision in a contract between Johnson & Johnson (NYSE: JNJ  ) and Schering-Plough, Merck set up its acquisition of Schering-Plough so that Schering-Plough technically bought Merck in a reverse merger and then changed its name to Merck. Johnson & Johnson cried foul and took the entity formerly known as Schering-Plough to arbitration, claiming full rights to anti-inflammatory Remicade and its follow up Simponi that Schering-Plough marketed for Johnson & Johnson outside the U.S.

Rather than let an arbiter make the final decision, the two sides decided to hash out a compromise. Under the terms of the new agreement, Merck retains territories that make up about 70% of the current revenue it gets from selling the two drugs. In those regions Merck also has to pay Johnson & Johnson more of the profit than it had been, bumping the Johnson & Johnson's share from 42% up to 50%. Additionally Merck has to make a one-time payment of $500 million for the privilege of giving up part of its rights.

It's tempting to declare Johnson & Johnson the winner here -- it does, after all, have more than it did before. But Merck could have lost the entire $2.8 billion in revenue it brings in from the drugs with one pound of the gavel. A settlement lifts the clouds that have been hanging over Merck's shares for over a year. Considering both companies are up today, I think it's fair to call this one a draw.

With the uncertainty gone, the companies can get back to marketing Remicade and Simponi in their three way battle with Abbott Labs' (NYSE: ABT  ) Humira and Enbrel from Pfizer (NYSE: PFE  ) and Amgen (Nasdaq: AMGN  ) , while preparing for the upcoming onslaught from oral medications being developed by Pfizer, Rigel Pharmaceuticals (Nasdaq: RIGL  ) , and others.

Uncertain about where the market is going? Watch this before the market crashes.

Johnson & Johnson and Pfizer are Motley Fool Inside Value picks. Johnson & Johnson is a Motley Fool Income Investor pick. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Abbott Laboratories, and Johnson & Johnson. Alpha Newsletter Account, LLC owns shares of Abbott Laboratories and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1476424, ~/Articles/ArticleHandler.aspx, 10/21/2014 3:03:24 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement